跳至主要内容
临床试验/NCT06066918
NCT06066918招募中不适用

The Effect of Preventional Drug Therapy on Pain Regulation Mechanisms Among Spinal Cord Injury Patients Who Have Yet to Develop Central Pain

Loewenstein Hospital1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2021年7月13日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
50
试验地点
1
主要终点
Central pain

研究概览

简要总结

Patients arriving to rehabilitation up to 3 months following SCI will be given (study group) or not (control group) Lyrica (75X2). They will be followed for central pain development.

详细描述

Patients arriving to rehabilitation up to 3 months following SCI will be recruited, if they have not yet developed central pain. Two thirds (the study group) will be treated with Lyrica (Pregabalin75X2) for 3 months. One third (the control group) will not receive preventative treatment. Participants will be followed for central pain development.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Up to 3 months following traumatic or non-traumatic SCL
  • Ability to give informed consent and cooperate

排除标准

  • Pregnancy
  • Neurological or other medical conditions that may interfere with sensation
  • Neuropathic-like pain before recruitment (described as painful sensation of electric current, burning, numbness, tingling, pricking, or squeezing)
  • Being treated with Pregabalin
  • Blood creatinine levels >1.2 or creatinine clearance <60
  • Sensitivity to lactose

研究组 & 干预措施

Pregabalin

Experimental

Pregabalin 75 mg X2

干预措施: Pregabalin 75mg (Drug)

结局指标

主要结局

Central pain

时间窗: 1 year

development of central pain by interview (yes /no )

McGill Pain Questionnaire

时间窗: 3 months

Range 0 -78. higher scores mean worse outcome.

次要结局

未报告次要终点

研究者

发起方
Loewenstein Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

amiram-catz

Principal Investigator

Loewenstein Hospital

研究点 (1)

Loading locations...

相似试验